WILMINGTON, Del., Oct. 29, 2024 (Globe Newswire) — Aimfinity Investment Corp. I (the “Company” or “AIMA”), a special purpose acquisition company organized as a Cayman Islands exempt company (Nasdaq : AIMAU) today announced that the Company is extending the deadline by which the Company must complete its initial business combination from October 28, 2024 to November 28, 2024 to extend the deadline by which the Company must complete its initial business combination from October 28, 2024 to November 28, 2024. Mr. Chang will deposit into that trust account (the “Trust Account”) an aggregate amount of $60,000 (the “Monthly Extension Payment”) on October 28, 2024.
Pursuant to the Company’s Third Amended and Restated Memorandum and Articles of Incorporation (the “Current Articles of Incorporation”), effective April 23, 2024, the Company shall operate from April 28, 2024 to January 28, 2025, or You can extend by month to an earlier date. The board of directors may decide to consummate the business combination by depositing monthly extension payments into a trust account. This is the seventh of nine monthly extensions required under our current charter.
About I’mfinity Investment Corporation I
Aimfinity Investment Corp. I is incorporated as a Cayman Islands exempt company for the purpose of effecting a merger, stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more companies or entities. It’s a blank check company. We have not selected any targets for our business combination, nor have we entered into any substantive discussions, directly or indirectly, with any target of our business combination with respect to our initial business combination, nor has anyone represented us. Although we are not limited to any particular industry or geographic region in identifying and acquiring target companies, we may complete an initial business combination with a target company headquartered in China (including Hong Kong and Macau) will not be executed. The majority of our business is conducted in China (including Hong Kong and Macau).
Additional information and where to find it
As previously disclosed, on October 13, 2023, the Company entered into certain agreements and plans of merger between the Company and Docter, as may be amended, supplemented or otherwise amended from time to time. The “Merger Agreement”) has been concluded. Aimfinity Investment Merger Sub I, a Delaware corporation, Aimfinity Investment Merger Sub II, a Cayman Islands exempt company and wholly owned subsidiary of its parent company (“Purchaser”), and Aimfinity Investment Merger Sub II, Inc., a Delaware corporation. Based on this, the Company proposes to enter into a business combination with Doctor through a restructuring merger and an acquisition merger. This press release does not contain all the information you should consider with respect to the proposed business combination and is not intended to form the basis of any investment or other decisions regarding the business combination. AIMA stockholders and other interested parties are encouraged to read the proxy statement/prospectus and any amendments thereto, as well as any other documents filed in connection with the proposed business combination, when available. Recommended. These materials contain important information about AIMA, the Buyer or the Doctor, and the proposed business combination. If available, the proxy statement/prospectus and other related materials regarding the proposed business combination will be mailed to AIMA stockholders as of the record date established for voting on the proposed business combination. Such stockholders may obtain copies of the proxy statement/prospectus and other documents filed with the Securities and Exchange Commission (“SEC”), free of charge, when they become available on the SEC’s website at www.sec.gov. You can also. By submitting your request to AIMA headquarters, 221 W 9th St, PMB 235 Wilmington, Delaware 19801.
Forward-looking statements
This press release contains certain “forward-looking statements” within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. Statements contained herein that are not historical facts, including statements regarding pending transactions and the parties’ prospects and expectations, are forward-looking statements. Such statements include, but are not limited to, the expected initial enterprise value and post-closing equity value, the benefits of the proposed transaction, integration plans, expected synergies and revenue opportunities, and expected future financial and operating results. including, but not limited to, statements regarding transactions made. performance and results, including expected growth, the expected management and governance of the combined company and the expected timing of the transaction; The words “expect,” “believe,” “estimate,” “intend,” “plan” and similar expressions identify forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to various known and unknown risks, uncertainties and assumptions, including assumptions regarding general economic, market, industry and operational factors. actual results may differ materially. what is shown or expected.
Such risks and uncertainties include, but are not limited to: (i) risks related to the anticipated timing and likelihood of completion of the pending business combination, including the risk that the transaction may not be completed due to one or more of the transaction’s closing conditions; the failure to satisfy or waive, including the failure to obtain timely or untimely regulatory approvals or the prohibition, delay or refusal of any governmental authority to obtain approval to complete the transaction; and that we require certain conditions, restrictions and limitations, if any such approval. (ii) risks related to AIMA and Doctor’s ability to successfully integrate their businesses; (iii) the occurrence of events, changes, or other circumstances that may cause the termination of the applicable Transaction Agreement; (iv) risks that could have a material adverse effect on AIMA’s or Docter’s financial condition, results of operations, operations or prospects; (v) risks related to disruptions to management time due to continued business operations resulting from the proposed transaction; (vi) the risk that announcements regarding the proposed transaction may adversely affect the market price of AIMA’s securities; (vii) the proposed transaction and its announcement would adversely affect Docter’s ability to retain customers, retain and employ key personnel, maintain relationships with suppliers and customers, and its results of operations and business generally; Possible risks. (viii): risks associated with the medical device industry, including without limitation changes in government regulations and enforcement, market competition, competitive products and pricing activities; (ix) risks related to the combined company’s ability to enhance its products and services, execute its business strategy, expand its customer base and maintain stable relationships with its business partners;
A further list and description of risks and uncertainties can be found in the prospectus filed on April 26, 2022, Form 10-K for the fiscal year ended December 31, 2022 in connection with AIMA’s initial public offering. In AIMA’s annual report. dated April 17, 2023, and the registration statement/proxy statement that AIMA and/or its affiliates will file with the SEC in connection with the proposed transaction, and any other documents that the parties will file or submit to the SEC. Please read it. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, actual results may differ from those indicated or anticipated by such forward-looking statements. The results may differ significantly from those shown. You are therefore cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only as of the date on which they are made and, except as required by law or applicable regulation, Aimfinity, Docter and its subsidiaries do not anticipate any future events or circumstances after the date on which they are made. We undertake no obligation to update any forward-looking statements to reflect any future changes.
Prohibition of offers and solicitations
This press release is not a proxy or the solicitation of a proxy, an agreement or authorization with respect to any securities or potential transactions, and does not constitute an offer to sell or the solicitation of an offer to buy any securities of AIMA. Purchaser or Physician may not sell such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No. No offering of securities shall be made except by means of a prospectus meeting the requirements of securities laws.
Recruited participants
AIMA, Docter and their respective directors, executive officers, other management and employees may be considered participants in the solicitation of proxies from AIMA stockholders in connection with the proposed transaction under SEC rules. Under SEC rules, information regarding the persons who will be considered participants in AIMA’s solicitation of stockholders in connection with the proposed business combination will be included in the proxy statement/prospectus on Form F-4 filed with the SEC.
contact address:
I’mfinity Investment Corporation I
Ifa Chan
chief executive officer
ceo@aimfinityspac.com
(425) 365-2933
221 W 9th St, PMB 235
Wilmington, Delaware 19801
